Cancer Family

Breast Neoplasm

Non-malignant2,894 active trials43 approved drugs310 evidence items

NCIt: C2910
OncoTree: BNNOS
MeSH: D000069584
MeSH: D001943

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Literature

Linked publications (268)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 76–100 of 268 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Construction and application of mammary and breast cancer organoids.
Yuan Meng, Pinyang Bai, Lingxian Zhang et al. · Cell Insight · Oct 1, 2026 · PMID 42733592 · candidate dictionary pubmed
Development and evaluation of clinical models based on ultrasound, serum CA153 and molecular subtype in predicting the efficacy of neoadjuvant chemotherapy in breast cancer.
Ming-Yue Du, Shu-E Zeng · Oncol Lett · Oct 1, 2026 · PMID 42741650 · candidate dictionary pubmed
Systemic therapy-induced resistance and toxicity in breast cancer: Sensitization and mitigation strategies.
Anuveda Sree Samudrala, Ganji Purnachandra Nagaraju, RamaRao Malla · Biochim Biophys Acta Rev Cancer · Oct 1, 2026 · PMID 42669386 · candidate dictionary pubmed
Standardizing imaging-confirmed nodal assessment in early breast cancer: the case for c,iN0.
Wiebren A A Tjalma · Breast · Oct 1, 2026 · PMID 42697808 · candidate dictionary pubmed
Oncotype DX-guided vs physician-directed chemotherapy and survival in HR+/HER2- breast cancer.
Jingkun Li, Xinhao Han, Yan Zhuang et al. · Breast · Oct 1, 2026 · PMID 42659874 · candidate dictionary pubmed
Exceptional Locoregional Pathological Response in Metastatic Triple-Negative Breast Cancer Treated With Palliative Platinum-Based Chemotherapy.
Shristi Gupta, Abhisek Jha, Asmita Rayamajhi et al. · Clin Case Rep · Oct 1, 2026 · PMID 42787485 · candidate dictionary pubmed
Severe hyponatremia following low-dose cyclophosphamide in a patient with breast cancer: a case report.

Çiğdem Cindoğlu, Fatma Zehra Ağan · Int Cancer Conf J · Oct 1, 2026 · PMID 42781081 · candidate dictionary pubmed

Interrupted surveillance and delayed genetic evaluation in neurofibromatosis type 1 associated with advanced malignant peripheral nerve sheath tumor and breast cancer: A case report.

Mihoko Doi, Maiko Tanaka, Kanako Iwami et al. · Int Cancer Conf J · Oct 1, 2026 · PMID 42781021 · candidate dictionary pubmed

Navigating lymphatic drainage uncertainty in abdominal ectopic breast cancer: a novel application of indocyanine green fluorescence-a case report and literature review.

Alessio Vinci, Nadia Khitab, Hasan Asfour et al. · Int Cancer Conf J · Oct 1, 2026 · PMID 42780454 · candidate dictionary pubmed

Patient perspective on lymphoedema after breast cancer: evidence for 3D micro-massage compression.

Sian Pearce, Lorraine Nisbet · Br J Community Nurs · Oct 1, 2026 · PMID 42771673 · candidate dictionary pubmed

Association of statin use and left ventricular function in patients with breast cancer receiving trastuzumab.

Kotaro Nochioka, Yosuke Terui, Aika Udagawa et al. · Am Heart J Plus · Oct 1, 2026 · PMID 42761834 · candidate dictionary pubmed

Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.

· N Engl J Med · 2019 · PMID 31091374 · validated civic_curation pubmed

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.

· N Engl J Med · 2021 · PMID 34081848 · validated civic_curation pubmed

Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial.

· JAMA Oncol · 2021 · PMID 33480963 · validated civic_curation pubmed

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

· Lancet Oncol · 2016 · PMID 26874901 · validated civic_curation pubmed

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

· N Engl J Med · 2005 · PMID 16236737 · validated civic_curation pubmed

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.

· J Clin Oncol · 2022 · PMID 35584336 · validated civic_curation pubmed

Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.

· N Engl J Med · 2023 · PMID 37256976 · validated civic_curation pubmed

US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast Cancer.

· J Clin Oncol · 2025 · PMID 40845250 · validated civic_curation pubmed

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

· N Engl J Med · 2001 · PMID 11248153 · validated civic_curation pubmed

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

· J Clin Oncol · 2005 · PMID 15911866 · validated civic_curation pubmed

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.

· N Engl J Med · 2015 · PMID 25693012 · validated civic_curation pubmed

Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer.

· J Natl Cancer Inst · 2021 · PMID 32940689 · validated civic_curation pubmed

FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1.

· Breast Cancer Res · 2021 · PMID 33579347 · validated civic_curation pubmed

Cyclin D1 in breast cancer pathogenesis.

· J Clin Oncol · 2005 · PMID 15961768 · validated civic_curation pubmed